안녕하세요! 저희는 Nemo입니다.
Nemo는 'Never Miss Out(기회를 놓치지 마세요)'의 약자로, 데이터 기반으로 엄선한 투자 아이디어를 손안에서 바로 확인할 수 있는 모바일 투자 플랫폼입니다. 주식, ETF, 암호화폐, CFD를 수수료 없이 거래할 수 있으며, AI 기반 도구, 실시간 시장 알림, 그리고 Nemes라고 불리는 테마별 주식 컬렉션을 제공합니다.
앱 다운로드
QR 코드를 스캔하여 Nemo 앱을 다운로드하고 지금 바로 Nemo에서 투자를 시작하세요
2026년 10월 30일 게시
기사 읽기
2026년 10월 30일 게시
기사 읽기
2026년 10월 30일 게시
기사 읽기
2026년 10월 29일 게시
기사 읽기
2026년 10월 28일 게시
기사 읽기
I’ve always found the idea of owning a factory rather dreadful. The constant worry about supply chains, union disputes, and whether anyone will actually buy the widgets you’re churning out. It all sounds terribly stressful. Now, compare that to owning the rights to a hit song. You write it once, and for the next fifty years, a small cheque might arrive every time it’s played on the radio, used in a film, or streamed by a teenager in Tokyo. One involves grease and headaches, the other involves a letterbox. To me, the choice seems rather obvious.
This, in a nutshell, is the appeal of investing in intellectual property, or IP. It’s the business of owning ideas, not things. And in our increasingly digital world, it’s a theme that I think investors would be foolish to ignore, provided they understand the risks.
Let’s be clear, this isn’t some fanciful concept. There are companies whose entire business model is built on this elegant premise. Take a firm like Royalty Pharma. They don’t discover drugs, they don’t manufacture pills, and they certainly don’t deal with patients. Instead, they buy up the royalty rights to successful pharmaceuticals developed by others. When a big pharma company sells a drug using that patent, Royalty Pharma gets a cut.
The beauty of this is the margin. There are no factory overheads, no inventory to manage, no logistical nightmares. It’s one of the purest revenue streams you can find. The hard work, the billions spent on research and development that might lead nowhere, has already been done by someone else. These companies simply swoop in to collect potential rewards from proven winners. It’s a wonderfully pragmatic way to operate.
This isn’t just about medicine, of course. The principle applies everywhere. Disney has been the master of this for decades. They created a mouse nearly a century ago, and they are still collecting royalties from every t-shirt, lunchbox, and theme park ticket that bears his image. The initial creative effort could pay dividends, again and again, across generations and continents.
Then you have the technology sector, which is a veritable goldmine for IP. A company like Qualcomm doesn’t need to build a single smartphone to profit from the entire industry’s growth. They own fundamental patents for wireless technology. So, every time a phone maker builds a device that connects to a 5G network, Qualcomm may get a licensing fee. As the world becomes more connected, their library of ideas could become ever more valuable.
Now, before you rush off thinking this is a risk-free path to riches, let’s pour a little cold water on the idea. Investing in IP has its own unique set of traps. The most obvious is the patent cliff. A patent, unlike a diamond, is not forever. When it expires, that gusher of royalty income can dry up overnight. A blockbuster drug can go from a cash cow to practically worthless in a heartbeat.
Furthermore, technology and tastes change. A patent for a revolutionary piece of tech can be rendered obsolete by the next big thing. And the pop song that’s generating millions today might be forgotten tomorrow. Consumer whims are a fickle foundation on which to build an empire. You are betting that an idea will remain relevant, which is never a certainty.
So, what’s the verdict? To me, intellectual property represents a fascinating and modern way to diversify. These companies often dance to a different tune than the broader economy. People might stop buying new cars during a recession, but they’ll probably keep streaming music and taking their prescribed medication. This could add a layer of resilience to a portfolio.
The challenge has often been getting access. You can’t exactly pop down to the shops and buy a slice of a drug patent. However, you can invest in the companies that own these rights. Exploring a curated collection of these firms, like the Intellectual Property Titans basket, could be a way to gain exposure to this theme without putting all your eggs in one patent-protected basket. It’s a way of betting on human ingenuity itself, and while that carries risks, it’s also one of the most powerful forces on the planet.
전체 바스켓 보기:Intellectual Property Royalties
본 기사는 마케팅 자료이며 투자 조언으로 해석되어서는 안 됩니다. 본 기사에 포함된 어떠한 정보도 금융 상품의 매수 또는 매도에 대한 조언, 추천, 제안 또는 권유로 간주되어서는 안 되며, 금융, 투자 또는 거래 조언에 해당하지 않습니다. 특정 금융 상품이나 투자 전략에 대한 언급은 예시 및 교육 목적으로만 제공되며 사전 통지 없이 변경될 수 있습니다. 투자 예정 대상을 평가하고, 본인의 재무 상황을 검토하고, 독립적인 전문가의 조언을 구하는 것은 투자자 본인의 책임입니다. 과거의 성과가 미래의 결과를 보장하지 않습니다. 자세한 내용은 다음 문서를 참조하십시오: 리스크 고지.
2026년 10월 30일 게시
기사 읽기
2026년 10월 30일 게시
기사 읽기
2026년 10월 30일 게시
기사 읽기
2026년 10월 29일 게시
기사 읽기
2026년 10월 28일 게시
기사 읽기
